Bordeaux, France December 15, 2021 – FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER^®, an Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, today announced further funding of €6 million bringing the Series B total to €21 million, giving FineHeart a cash runway until the end of 2023. This financing comes in addition to the €15 million raised in June 2021 with the pool of industrial and independent investors: Lauak Group, Doliam, FineHeart Founders’ Holding which brought together international private investors, mainly from the cardiology sector and the European investment fund Verve Ventures. They joined historical shareholders Irdi, Aquiti, Galia, Broadview Ventures, and M Capital.

“I am extremely pleased with the interest our project is attracting from new investors who are joining the original and innovative consortium, which we brought together in previous rounds. This further sign of confidence in our strategy allows us to move ahead with the next steps in the development of the ICOMS FLOWMAKER^® and the First In Human clinical trials in 2022”, declared Arnaud Mascarell, CEO & Co-founder of FineHeart. “Our goal is to bring an effective treatment to thousands of patients suffering from severe heart failure as quickly as possible, thanks to our disruptive, fully implantable device, with no external wires or batteries, which will enable them to lead a normal life again.”

Sylvain Famier, President of Med-INNOV, one of the investors in this new round of financing, said: “We are delighted to add FineHeart to our portfolio of highly innovative French companies that are inventing the healthcare of tomorrow. The ICOMS FLOWMAKER^® technology isrevolutionary and unique. We are convinced that it has all the functionalities to effectively treat severe heart failure effectively”.